Eli Lilly partners with Metis TechBio on AI‑driven lipid‑nanoparticle delivery platform
Eli Lilly has entered a research collaboration with Hong‑Kong‑listed Metis TechBio to develop AI‑guided lipid‑nanoparticle (LNP) delivery technologies. The deal can total up to $1.1 billion, with an upfront payment in the low double‑digit‑million‑dollar range and tiered royalties at a single‑digit percentage of net sales. The partnership targets tissue‑specific delivery for genetic medicines and follows Lilly’s recent acquisitions of delivery platforms.
Why it matters
The upfront amount is under $100 million, representing less than 0.7% of Lilly’s $14.60 billion annual R&D spend, giving the company a low‑cost option to expand its genetic‑medicine pipeline. If milestones are met, the total payout would equal roughly 7.5% of one year of Lilly’s R&D budget, potentially affecting future R&D budgeting and earnings.
Key facts
- 1The collaboration can provide up to $1.1 billion in total payments, contingent on development, regulatory and commercial milestones. finance.yahoo.com
- 2Lilly will make an upfront payment in the low double‑digit millions of dollars (below $100 million). finance.yahoo.com
- 3Royalties are tiered at a single‑digit percentage of net sales. finance.yahoo.com
- 4Lilly’s R&D spending over the last 12 months was $14.60 billion. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.